RVLP logo

RVL Pharmaceuticals (RVLP) Depreciation And Amortization

RVLP Annual D&A

$375.00 K
-$7.80 M-95.41%

31 December 2022

1-Year Change

-95.41%
RVLP annual depreciation & amortization is down -95.41% year-on-year

3-Year Change

-99.34%
RVLP annual depreciation & amortization is down -99.34% over the past 3 years

All-time High

$81.57 M
RVLP annual depreciation & amortization is currently -99.54% below its historical high of $81.57 million
Annual Total Expenses$95.40 M
RVLP annual total expenses is $95.40 million
Annual Operating Expenses$85.94 M
RVLP annual total operating expenses is $85.94 million
Annual Revenue$49.72 M
RVLP annual revenue is $49.72 million
Annual Net Income-$51.69 M
RVLP annual net profit is -$51.69 million

RVLP Depreciation And Amortization Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

RVLP Quarterly D&A

$94.00 K
+$1000.00+1.08%

30 June 2023

1-Year Change

+3.3%
RVLP quarterly depreciation & amortization is up +3.3% year-on-year

3-Year Change

+101.82%
RVLP quarterly depreciation & amortization is up +101.82% over the past 3 years

All-time High

$20.46 M
RVLP quarterly depreciation & amortization is currently -99.54% below its historical high of $20.46 million
Quarterly Total Expenses$16.38 M
RVLP quarterly total expenses is $16.38 million
Quarterly Operating Expenses$14.43 M
RVLP quarterly total operating expenses is $14.43 million
Quarterly Revenue$8.26 M
RVLP quarterly revenue is $8.26 million
Quarterly Net Income-$23.89 M
RVLP quarterly net profit is -$23.89 million

RVLP Quarterly D&A Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

RVLP TTM D&A

$382.00 K
+$3000.00+0.79%

30 June 2023

1-Year Change

-13.38%
RVLP TTM depreciation & amortization is down -13.38% year-on-year

3-Year Change

-98.22%
RVLP TTM depreciation & amortization is down -98.22% over the past 3 years

All-time High

$81.57 M
RVLP TTM depreciation & amortization is currently -99.53% below its historical high of $81.57 million
Annual Total Expenses$95.40 M
RVLP annual total expenses is $95.40 million
Annual Operating Expenses$85.94 M
RVLP annual total operating expenses is $85.94 million
TTM Revenue$36.92 M
RVLP TTM revenue is $36.92 million
TTM Net Income-$68.27 M
RVLP TTM net profit is -$68.27 million

RVLP TTM D&A Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

RVLP Depreciation And Amortization Performance

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-95.4%+3.3%-13.4%
3 y3 years-99.3%+101.8%-98.2%
5 y5 years-99.2%-99.5%-99.3%

RVLP Depreciation And Amortization High & Low

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year
5 y5-year
alltimeall time-99.5%-99.5%-99.5%

RVL Pharmaceuticals Depreciation And Amortization History

DateAnnualQuarterlyTTM
June 2023
-
$94.00 K(+1.1%)
$382.00 K(+0.8%)
Mar 2023
-
$93.00 K(-7.0%)
$379.00 K(+1.1%)
Dec 2022
$375.00 K(-95.4%)
$100.00 K(+5.3%)
$375.00 K(-1.8%)
Sept 2022
-
$95.00 K(+4.4%)
$382.00 K(-13.4%)
June 2022
-
$91.00 K(+2.2%)
$441.00 K(-89.7%)
Mar 2022
-
$89.00 K(-16.8%)
$4.28 M(-47.7%)
Dec 2021
$8.18 M(-61.1%)
$107.00 K(-30.5%)
$8.18 M(-34.6%)
Sept 2021
-
$154.00 K(-96.1%)
$12.51 M(-56.2%)
June 2021
-
$3.93 M(-1.5%)
$28.53 M(+46.7%)
Mar 2021
-
$3.99 M(-10.2%)
$19.45 M(-7.5%)
Dec 2020
$21.03 M
$4.44 M(-72.6%)
$21.03 M(-8.6%)
Sept 2020
-
$16.18 M(-413.9%)
$23.00 M(+7.3%)
DateAnnualQuarterlyTTM
June 2020
-
-$5.16 M(-192.7%)
$21.43 M(-51.9%)
Mar 2020
-
$5.56 M(-13.2%)
$44.58 M(-21.8%)
Dec 2019
$57.02 M(-30.1%)
$6.41 M(-56.1%)
$57.02 M(-19.5%)
Sept 2019
-
$14.61 M(-18.8%)
$70.85 M(-7.6%)
June 2019
-
$18.00 M(+0.0%)
$76.70 M(-3.1%)
Mar 2019
-
$17.99 M(-11.1%)
$79.15 M(-3.0%)
Dec 2018
$81.57 M(+75.6%)
$20.25 M(-1.0%)
$81.57 M(+33.0%)
Sept 2018
-
$20.46 M(+0.0%)
$61.32 M(+50.1%)
June 2018
-
$20.45 M(+0.2%)
$40.87 M(+100.2%)
Mar 2018
-
$20.41 M
$20.41 M
Dec 2017
$46.45 M(+96.9%)
-
-
Dec 2016
$23.59 M
-
-

FAQ

  • What is RVL Pharmaceuticals annual depreciation & amortization?
  • What is the all time high annual D&A for RVL Pharmaceuticals?
  • What is RVL Pharmaceuticals annual D&A year-on-year change?
  • What is RVL Pharmaceuticals quarterly depreciation & amortization?
  • What is the all time high quarterly D&A for RVL Pharmaceuticals?
  • What is RVL Pharmaceuticals quarterly D&A year-on-year change?
  • What is RVL Pharmaceuticals TTM depreciation & amortization?
  • What is the all time high TTM D&A for RVL Pharmaceuticals?
  • What is RVL Pharmaceuticals TTM D&A year-on-year change?

What is RVL Pharmaceuticals annual depreciation & amortization?

The current annual D&A of RVLP is $375.00 K

What is the all time high annual D&A for RVL Pharmaceuticals?

RVL Pharmaceuticals all-time high annual depreciation & amortization is $81.57 M

What is RVL Pharmaceuticals annual D&A year-on-year change?

Over the past year, RVLP annual depreciation & amortization has changed by -$7.80 M (-95.41%)

What is RVL Pharmaceuticals quarterly depreciation & amortization?

The current quarterly D&A of RVLP is $94.00 K

What is the all time high quarterly D&A for RVL Pharmaceuticals?

RVL Pharmaceuticals all-time high quarterly depreciation & amortization is $20.46 M

What is RVL Pharmaceuticals quarterly D&A year-on-year change?

Over the past year, RVLP quarterly depreciation & amortization has changed by +$3000.00 (+3.30%)

What is RVL Pharmaceuticals TTM depreciation & amortization?

The current TTM D&A of RVLP is $382.00 K

What is the all time high TTM D&A for RVL Pharmaceuticals?

RVL Pharmaceuticals all-time high TTM depreciation & amortization is $81.57 M

What is RVL Pharmaceuticals TTM D&A year-on-year change?

Over the past year, RVLP TTM depreciation & amortization has changed by -$59.00 K (-13.38%)